The present disclosure provides a method for determining the amount of albumin in a sample. In one embodiment, the method involves treating the sample with an esterase inhibitor that selectively inhibits non-albumin esterase activity; combining the sample with a selective substrate of albumin, which has a carboxylic ester bond, so that the carboxylic ester bond is cleaved to generate a hydrolysate; detecting the amount of the hydrolysate generated in a period of time; and determining the amount of the albumin in the sample based on the amount of the hydrolysate in the period of time.

In the analysis method according to the present invention, a predetermined peptide is separated by immunoprecipitation using an antibody which specifically binds to either an N-terminus or a C-terminus of the predetermined peptide. The separated predetermined peptide is digested with a protease to prepare peptide fragments, and among the peptide fragments, a peptide fragment at a terminus opposite to a terminus binding to the antibody is mass-spectrometrically detected.

Provided herein is the use of measurements of cell-free DNA, protein, and/or metabolite found in biofluid (e.g., urine) for identifying and treating organ injury. Provided herein are methods and compositions for monitoring, detecting, quantifying, and treating kidney injury in subjects suffering from or suspected of having an altered renal status by measuring amounts of cfDNA and one or more other markers, such as inflammation markers, apoptosis markers, protein, and DNA methylation.

This application relates to the use of measurements of cell-free DNA, protein, and/or metabolite found in biofluid (e.g., urine) for identifying and treating organ injury. The application includes methods and compositions for monitoring, detecting, quantifying, and treating kidney injury in subjects suffering from or suspected of having an altered renal status by measuring amounts of cfDNA and one or more other markers, such as inflammation markers, apoptosis markers, protein, and DNA methylation.

Disclosed is a test strip for detecting microalbumin in urine, and more particularly a test strip for detecting microalbumin in urine that contains a synthetic albumin indicator, a buffer solution, a surfactant and a polymer (sensitizer) and thus exhibits high sensitivity. The albumin detection test strip has accuracy sufficient to enable clear observation of color change from colorless to blue through the albumin indicator, and improves the detection limit (increases sensitivity) to thereby enable detection of microalbuminuria at a concentration of 20 mg/L or less. The albumin test detection strip contains a surfactant and a polymer in addition to a synthetic albumin indicator, thereby incorporating separate first and second processes into a single process and having effects of reducing costs, improving processing convenience, and increasing solubility and miscibility.

A urine sample testing apparatus may include a urine qualitative measuring section configured to acquire a measurement result for each of a plurality of urine qualitative measurement items and a urine sediment measuring section configured to acquire a measurement result for each of a plurality of urine sediment measurement items. The apparatus may also include an operation part that can specify a combination of one of the plurality of urine qualitative measurement items and one of the plurality of urine sediment measurement items. An information processing unit may also be included.

Provided is a reagent composition for measuring glycated albumin to diagnose the presence or absence of diabetes and a method of measuring glycated albumin using the same, and more particularly is a reagent composition for measuring glycated albumin, the composition including a dye-encapsulated silica nanoparticle-boronic acid, and to a method of measuring glycated albumin using the same. In the reagent composition for measuring glycated albumin, since a dye is encapsulated in silica nanoparticles, the inherent absorption wavelength of the dye is not affected by pH and the composition has excellent stability even when stored for one month or more.

This application relates to the use of measurements of cell-free DNA, protein, and/or metabolite found in biofluid (e.g., urine) for identifying and treating organ injury. The application includes methods and compositions for monitoring, detecting, quantifying, and treating kidney injury in subjects suffering from or suspected of having an altered renal status by measuring amounts of cfDNA and one or more other markers, such as inflammation markers, apoptosis markers, protein, and DNA methylation.

The invention relates to the field of biology and medicine, specifically to oncology, and can be used for diagnosing prostate cancer. For this purpose, use is made of a novel prostate cancer marker, which can be identified in the urine of a patient and constitutes of integrin-alpha V level or a fragment thereof. A method of diagnosing prostate cancer, comprising identifying integrin-alpha V in the urine of a patient, and a kit for carrying out the diagnosis, comprising at least one antibody specific to integrin-alpha V, or a functional fragment thereof, are also proposed. The invention makes it possible to carry out a non-invasive diagnosis of prostate cancer using a simple, sensitive and reliable method, which can be used under standard clinical laboratory conditions in inpatient or outpatient medical institutions.

The present disclosure describes a method of quantifying amounts of phosphopeptides using isotopically-enriched peptides as internal standards. A kit comprising at least one isotopically-enriched phosphorylated peptide can be used to quantify changes in amounts of phosphopeptides using parallel reaction monitoring mass spectrometry techniques. The invention can be used to indicate the pathologic mechanism, severity of the disease, and treatment response of a subject. The invention can also be used to identify subjects who require more aggressive therapeutic interventions or alternative treatments.